Dr. Yom is a radiation oncologist who specializes in the treatment of head and neck and lung cancers. She received her M.D. from the University of Pennsylvania in 2002 and completed her residency training at the prestigious M.D. Anderson Cancer Center in Houston, Texas. In 2007, she joined the UCSF faculty as an Assistant Professor of Clinical Radiation Oncology.
Dr. Yom is particularly interested in emerging radiotherapeutic and biologic techniques aimed at reducing the toxicities of treatment. In head and neck cancer, she has studied a variety of issues related to chemoradiation and combined modality treatments, technical aspects of radiation delivery, and radiation-related prognostic factors and post-treatment management. Specifically in lung cancer, she has been involved in efforts to quantify the risks of pneumonitis and esophagitis resulting from concurrent treatment with chemotherapy and radiation and helped to establish intensity-modulated radiation therapy in the treatment of locoregionally advanced lung cancers.
Evidencing her commitment to patient care and patient-oriented research, Dr. Yom has been the recipient of numerous awards including the ASTRO Fellowship from the Korean American Society for Therapeutic Radiology & Oncology, the Jesse H. Jones Fellowship in Cancer Education for excellence in cancer education at M.D. Anderson Cancer Center, an award from the A. Lavoy Moore Endowment Fund for excellence in lung cancer research, and the Eleanor Montague Distinguished Resident Award in Radiation Oncology from the American Association of Women Radiologists. She has authored numerous peer-reviewed articles and is a regularly invited speaker to fellow professionals in the field.
In lung cancer, Dr. Yom has conducted research quantifying the risks of pneumonitis and esophagitis when chemotherapy and radiation are given simultaneously. Her research findings were important in establishing the early use of intensity-modulated radiation therapy for lung cancer in combination with 4-dimensional CT-based planning. She has particular expertise in the delivery of chemoradiation therapy for advanced-stage lung cancer, and also the delivery of non-invasive stereotactic CyberKnife radiation for early-stage lung cancer. Her hope is that better understanding of radiation toxicities will permit higher treatment doses, increase the rate of cure and improve patient quality of life. She is strongly committed to research that will lead to more effective, less toxic, and more highly individualized therapy for patients.
Dr. Yom is an investigator on many research studies in head and neck and lung cancer at UCSF, including trials related to to image-guided radiation, head and neck patients' quality of life, and combinations of novel systemic agents with radiation therapy. She is especially interested in improved clinical and translational prognostic models in order to provide more effective and individualized therapy. It is hoped that the reduction of toxicities, both through technical and biologic means, will improve patients' quality of life and potentially enable physicians to deliver more intelligently targeted radiation and chemotherapy doses in search of a better chance of cure. She believes in multidisciplinary management and a unified, team-oriented approach to patient care
Heaton CM, Al-Shwaiheen F, Liu CS, Yom SS, Ryan WR. Prognostic significance of hyoid bone invasion in advanced base of tongue carcinoma treated by chemoradiation. Clin Otolaryngol. 2015 Jun; 40(3):260-5. View in PubMed
Wong RK, Deshmukh S, Wyatt G, Sagar S, Singh AK, Sultanem K, Nguyen-Tân PF, Yom SS, Cardinale J, Yao M, Hodson I, Matthiesen CL, Suh J, Thakrar H, Pugh SL, Berk L. Acupuncture-Like Transcutaneous Electrical Nerve Stimulation Versus Pilocarpine in Treating Radiation-Induced Xerostomia: Results of RTOG 0537 Phase 3 Study. Int J Radiat Oncol Biol Phys. 2015 Jun 1; 92(2):220-7. View in PubMed
Descovich M, McGuinness C, Kannarunimit D, Chen J, Pinnaduwage D, Pouliot J, Kased N, Gottschalk AR, Yom SS. Comparison between target margins derived from 4DCT scans and real-time tumor motion tracking: Insights from lung tumor patients treated with robotic radiosurgery. Med Phys. 2015 Mar; 42(3):1280. View in PubMed
Axelrod RS, Sherman E, Garden A, Nguyen-Tan PF, Trotti A, Yom SS, Zhang Q. Reply to d. Adkins et Al. J Clin Oncol. 2015 Apr 1; 33(10):1224-5. View in PubMed
Al-Shwaiheen FA, Wang SJ, Uzelac A, Yom SS, Ryan WR. The advantages and drawbacks of routine magnetic resonance imaging for long-term post-treatment locoregional surveillance of oral cavity squamous cell carcinoma. Am J Otolaryngol. 2015 May-Jun; 36(3):415-23. View in PubMed
Yom SS, Diehn M, Raben D. Molecular determinants of radiation response in non-small cell lung cancer. Semin Radiat Oncol. 2015 Apr; 25(2):67-77. View in PubMed
Yom SS. Accelerated repopulation as a cause of radiation treatment failure in non-small cell lung cancer: review of current data and future clinical strategies. Semin Radiat Oncol. 2015 Apr; 25(2):93-9. View in PubMed
Chyan A, Chen J, Shugard E, Lambert L, Quivey JM, Yom SS. Dosimetric predictors of hypothyroidism in oropharyngeal cancer patients treated with intensity-modulated radiation therapy. Radiat Oncol. 2014; 9:269. View in PubMed
Goepfert RP, Yom SS, Ryan WR, Cheung SW. Development of a chemoradiation therapy toxicity staging system for oropharyngeal carcinoma. Laryngoscope. 2015 Apr; 125(4):869-76. View in PubMed
Kannarunimit D, Descovich M, Garcia A, Chen J, Weinberg V, Mcguinness C, Pinnaduwage D, Murnane J, Gottschalk AR, Yom SS. Analysis of dose distribution and risk of pneumonitis in stereotactic body radiation therapy for centrally located lung tumors: a comparison of robotic radiosurgery, helical tomotherapy and volumetric modulated arc therapy. Technol Cancer Res Treat. 2015 Feb; 14(1):49-60. View in PubMed
Please note: UCSF Profiles publications are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact CTSI for help.